Definium Therapeutics, Inc. (DFTX) vs Option Care Health, Inc. (OPCH)
A side-by-side comparison of Definium Therapeutics, Inc. and Option Care Health, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DFTX
Definium Therapeutics, Inc.
$35.21HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
OPCH
Option Care Health, Inc.
$31.04HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — DFTX vs OPCH
growth of $100 · dividends reinvested · last 10yDFTX +971.9% (+26.8%/yr)OPCH +123.9% (+8.4%/yr)DFTX compounded faster over this window
DFTX OPCH
DFTX vs OPCH: by the numbers
- •DFTX is the larger company ($4.67B vs $4.65B market cap).
- •OPCH is profitable (3.68% net margin) while DFTX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | DFTX | OPCH |
|---|---|---|
| P/E ratio | N/A | 23.33 |
| Forward P/E | N/A | 16.51 |
| P/S ratio | N/A | 0.82 |
| P/B ratio | 5.09 | 3.69 |
| EV / EBITDA | N/A | 13.97 |
Profitability
| Metric | DFTX | OPCH |
|---|---|---|
| Gross margin | 0.00% | 18.17% |
| Operating margin | 0.00% | 5.94% |
| Net margin | 0.00% | 3.68% |
| ROE | -38.51% | 16.63% |
| ROIC | -23.81% | 9.68% |
Growth (annualized)
| Metric | DFTX | OPCH |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 12.17% |
| Total return CAGR (5Y) | 1.43% | -1.37% |
Frequently asked
- Is DFTX or OPCH more profitable?
- OPCH runs the higher net margin — DFTX at 0.00% versus OPCH at 3.68%.
- How have DFTX and OPCH total returns compared?
- Over the past 5 years, DFTX delivered 1.43% and OPCH delivered -1.37% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.